RxDoctor Payments Data

Julia Norem, MD

Family Medicine · Fayetteville, NCNPI 1881690402

Payments from drug & device makers

$756in general payments, 2019–2025

Across 24 payments — averaging $31.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$229
  • Lilly USA, LLC$177
  • Johnson & Johnson$110
  • Bayer$82
  • Baxter Healthcare$42
  • Sanofi-aventis U.S. LLC$38
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$756 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$277,187
Medicare patients
570
Services billed
4,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$94,389
TrulicityDulaglutide77$88,157
OzempicSemaglutide64$66,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$54,865
JanuviaSitagliptin Phosphate50$46,894
EliquisApixaban61$34,486
RybelsusSemaglutide26$22,261
Janumet XrSitagliptin Phos/Metformin Hcl34$21,021
XareltoRivaroxaban23$19,201
Tresiba Flextouch U-200Insulin Degludec18$18,952
MounjaroTirzepatide16$18,352
Spiriva HandihalerTiotropium Bromide24$17,929
FarxigaDapagliflozin Propanediol13$16,793
Victoza 3-PakLiraglutide11$13,330
Breo ElliptaFluticasone/Vilanterol19$12,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$177$106,50993 claims
Novo NordiskOzempic, Rybelsus$229$88,77590 claims
Johnson & JohnsonXarelto$110$19,20123 claims
AstraZenecaFarxiga$18$16,79313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →